CN102094020B - RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens - Google Patents

RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens Download PDF

Info

Publication number
CN102094020B
CN102094020B CN2010101089368A CN201010108936A CN102094020B CN 102094020 B CN102094020 B CN 102094020B CN 2010101089368 A CN2010101089368 A CN 2010101089368A CN 201010108936 A CN201010108936 A CN 201010108936A CN 102094020 B CN102094020 B CN 102094020B
Authority
CN
China
Prior art keywords
fut1
plasmid
dna
sequence
fut4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010101089368A
Other languages
Chinese (zh)
Other versions
CN102094020A (en
Inventor
张振波
闫杰
刘基巍
富力
王晓琦
燕秋
Original Assignee
燕秋
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 燕秋 filed Critical 燕秋
Priority to CN2010101089368A priority Critical patent/CN102094020B/en
Publication of CN102094020A publication Critical patent/CN102094020A/en
Application granted granted Critical
Publication of CN102094020B publication Critical patent/CN102094020B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an RNA (Ribose Nucleic Acid) interference sequence and a recombined interference plasmid for inhibiting a fucosyltransferase I synthesized by LeY carbohydrate antigens. The invention manly has the technical scheme that DNA sequences of respective 7 FUT1/FUT4 SiRNA templates of a fucosyltransferase I and a fucosyltransferase IV are designed and screened; recombined interference plasmids of the 7 FUT1 and the 7 FUT4 are constructed respectively on the basis of polyclone specific enzyme cutting sites of RNA interference vectors (pSilencer-4.1-CMVneo); and the recombined interference plasmids are used as anti-tumor drugs. The recombined interference plasmids have obvious tumor growth inhibiting effect; and in addition, the invention is an efficient, safe and economic tumor gene therapy mode.

Description

Be used to suppress the RNA interference sequence and the reorganization interfere plasmid of LeY CA synthetic fucosyl transferase I
The application is < the RNA interference sequence and the reorganization interfere plasmid that are used to suppress LeY CA synthetic fucosyl transferase I and IV>application number 200710010099.3,2007 the 01 month applying date, 15 days divide an application.
Technical field
The present invention relates to a kind of special dna sequence dna and according to the reorganization interfere plasmid of this sequence construct.
Background technology
Malignant tumour is a kind of disease of comparatively refractory, does not still have the ideal treat-ment.At present, mainly be to take comprehensive means such as surgical operation, radiotherapy and chemotherapy to the tumor treatment strategy, but each method still have limitation and can produce toxic side effect to a certain degree.
Summary of the invention
The object of the present invention is to provide a kind of according to the tomour specific CA synthetic and tumor growth, infiltration, transfer equimolecular mechanism constructed, the RNA that is used to suppress LeY tumour oligosaccharides antigen synthetic fucosyl transferase I and IV interferes sequence and the interfere plasmid of recombinating.The present invention mainly is: using the technological special CA with tumour of RNAi (RNAi, RNA interference) is target site, and it is antigenic synthetic to suppress cell surface Lewis Y (LeY) tumour oligosaccharides.The LeY molecular structure is Fuc α 1 → 2Ga1 β → 4 (Fuc α 1 → 3) GlcNAc); Promptly through designing and synthesizing antigenic key enzyme fucosyl transferase I (the Fucosyltransferase I of LeY tumour oligosaccharides; Be called for short FUT1) and fucosyl transferase I V (FucosyltransferaseIV; Abbreviation FUT4) the interference sequence of gene; And adopt the molecular cloning recombinant technology to make up reorganization FUT1 interfere plasmid (pSilencer-4.1-FUT1SiRNA) and reorganization FUT4 interfere plasmid (pSilencer-4.1-FUT4SiRNA), be used for antitumor drug and use.
Technical scheme of the present invention is following:
1. design and synthesize the interference sequence of FUT1 and FUT4 gene
Application of DNA STAR software analysis the homologous sequence of whole people's FUT1/FUT4 gene among the GenBank; The total length of the encoding sequence of FUT1/FUT4 gene is respectively 1098bp and 1218bp; The dna profiling sequence of the interfere plasmid of the reorganization FUT1/FUT4 that is used for neoplasm growth that obtains from the SiRNA design software is respectively chosen 7 as forming the template DNA sequences of interfering sequences, and length is 19bp.The interference sequence of the FUT1 gene that wherein, is designed is: FUT1-1:TGGCCGGTTTGGTAATCAG; FUT1-2:AGACTTTGCCCTGCTCACA; FUT1-3:GAGGAGTACGCGGACTTGA; FUT1-4:CAGATCCGCAGAGAGTTCA; FUT1-5:CGGCATGGAGTGGTGTAAA; FUT1-6:TGGCCTTCCTGCTAGTCTG; FUT1-7:TTCGCCTTTCCTCCCCTGC.The position of these sequences in the FUT1 gene is as shown in Figure 1.The interference sequence of the FUT4 gene that is designed is: FUT4-1:GCCTGGCAAGTAACCTCTT; FUT4-2:GTAACCTCTTCAACTGGAC; FUT4-3:CGGACGTCTTTGTGCCTTA; FUT4-4:CATGTGACCGTGGACGTGT; FUT4-5:GTTCTACCTGGCTTTCGAG; FUT4-6:CTCGTACCTGCTTTTCCTC; FUT4-7:GCGGAGGCAGCGCTGCCTG.The position of these sequences in the FUT4 gene is as shown in Figure 2.
2. make up reorganization FUT1 interfere plasmid and make up reorganization FUT4 interfere plasmid
1. obtain to be used for the dna profiling sequence of interfere plasmid of the reorganization FUT1/FUT4 of neoplasm growth according to the SiRNA design software, it is the structure that carries out interfere plasmid with the sequence of the control region of above-mentioned FUT1/FUT4 gene and coding region.
2. according to pSilencer-4.1-CMV-neo (Ambion; Inc) the dna profiling sequence of the FUT1/FUT4 interfere plasmid of carrier is inserted in the design of carrier structure information; Promptly the polyclone restriction enzyme site (HindIII, BamHI) with interference vector is the basis; Design the dna sequence dna that the FUT1/FUT4SiRNA template of identical sticky end is arranged with interference vector, make up 7 FUT1 interfere plasmids respectively: pSilencer-4.1-FUT1-1/FUT1-2/FUT1-3/FUT1-4/FUT1-5/FUT1-6/ FUT1-7; The interfere plasmid of 7 FUT4: pSilencer-4.1-FUT4-1/FUT4-2/FUT4-3/FUT4-4/FUT4-5/FUT4-6/ FUT4-7.The 5` end of every chain contains the restriction enzyme site (underscore marks) of HindIII or BamHI.Concrete sequence is following:
FUT1-1(5’-3’)
GATCCTGGCCGGTTTGGTAATCAGTTCAAGAGACTGATTACCAAACCGGCCAGGA
AGCTTCCTGGCCGGTTTGGTAATCAGTCTCTTGAACTGATTACCAAACCGGCCAG
FUT1-2(5’-3’)
GATCCAGACTTTGCCCTGCTCACATTCAAGAGATGTGAGCAGGGCAAAGTCTGGA
AGCTTCCAGACTTTGCCCTGCTCACATCTCTTGAATGTGAGCAGGGCAAAGTCTG
FUT1-3(5’-3’)
GATCCGAGGAGTACGCGGACTTGATTCAAGAGATCAAGTCCGCGTACTCCTCGGA
AGCTTCCGAGGAGTACGCGGACTTGATCTCTTGAATCAAGTCCGCGTACTCCTCG
FUT1-4(5’-3’)
GATCCCAGATCCGCAGAGAGTTCATTCAAGAGATGAACTCTCTGCGGATCTGGGA
AGCTTCCCAGATCCGCAGAGAGTTCATCTCTTGAATGAACTCTCTGCGGATCTGG
FUT1-5(5’-3’)
GATCCCGGCATGGAGTGGTGTAAATTCAAGAGATTTACACCACTCCATGCCGGGA
AGCTTCCCGGCATGGAGTGGTGTAAATCTCTTGAATTTACACCACTCCATGCCGG
FUT1-6(5’-3’)
GATCCTGGCCTTCCTGCTAGTCTGTTCAAGAGACAGACTAGCAGGAAGGCCAGGA
AGCTTCCTGGCCTTCCTGCTAGTCTGTCTCTTGAACAGACTAGCAGGAAGGCCAG
FUT1-7(5’-3’)
GATCCTTCGCCTTTCCTCCCCTGCTTCAAGAGAGCAGGGGAGGAAAGGCGAAGGA
AGCTTCCTTCGCCTTTCCTCCCCTGCTCTCTTGAAGCAGGGGAGGAAAGGCGAAG
FUT4-1(5’-3’)
GATCCGCCTGGCAAGTAACCTCTTCTCAAGAGAAAGAGGTTACTTGCCAGGCGGA
AGCTTCCAGCCTGGCAAGTAACCTCTTTCTCTTGAGAAGAGGTTACTTGCCAGGCG
FUT4-2(5`-3`)
GATCCGTAACCTCTTCAACTGGACTTCAAGAGAGTCCAGTTGAAGAGGTTACGGA
AGCTTCCGTAACCTCTTCAACTGGACTCTCTTGAAGTCCAGTTGAAGAGGTTACG
FUT4-3(5’-3’)
GATCCCGGACGTCTTTGTGCCTTATTCAAGAGATAAGGCACAAAGACGTCCGGGA
AGCTTCCCGGACGTCTTTGTGCCTTATCTCTTGAATAAGGCACAAAGACGTCCGG
FUT4-4(5’-3’)
GATCCCATGTGACCGTGGACGTGTTTCAAGAGAACACGTCCACGGTCACATGGGA
AGCTTCCCATGTGACCGTGGACGTGTTCTCTTGAAACACGTCCACGGTCACATGG
FUT4-5(5’-3’)
GATCCGTTCTACCTGGCTTTCGAGTTCAAGAGACTCGAAAGCCAGGTAGAACGGA
AGCTTCCGTTCTACCTGGCTTTCGAGTCTCTTGAACTCGAAAGCCAGGTAGAACG
FUT4-6(5’-3’)
GATCCCTCGTACCTGCTTTTCCTCTTCAAGAGAGAGGAAAAGCAGGTACGAGGGA
AGCTTCCCTCGTACCTGCTTTTCCTCTCTCTTGAAGAGGAAAAGCAGGTACGAGG
FUT4-7(5’-3’)
GATCCGCGGAGGCAGCGCTGCCTGTTCAAGAGACAGGCAGCGCTGCCTCCGCGGA
AGCTTCCGCGGAGGCAGCGCTGCCTGTCTCTTGAACAGGCAGCGCTGCCTCCGCG
3. after the special sequence synthetic (Takara company), form the double chain DNA sequence of the SiRNA template of 55bp (containing sticky end HindIII, BamHI) through sex change, annealing.Concrete grammar is: two chains of template DNA sequence that synthetic are used to disturb the SiRNA of FUT1/FUT4 gene; Use the dissolving of 10-100 μ l deionized water or TE (Tris-HCl EDTA) damping fluid respectively; And the light absorption value of mensuration 260nm, calculate its DNA concentration.With deionized water or TE dilution (10-500ng/ μ l).The strand sample of drawing dilution adds the DNA annealing buffer, and (contain 10mM Tris (pH7.4), 50mM NaCl 1mMEDTA) in 90-98 ℃ of sex change 3-10 minute, is cooled to 37 ℃ and kept 1 hour, preserves this annealing product in-20 ℃ of temperature, and is subsequent use.
4. pSilencer-4.1-FUT1/FUT4SiRNA construction of recombinant plasmid
Get pSilencer-4.1-CMV-neo (10-500ng) and carried out HindIII and BamHI double digestion 1-3 hour in 37 ℃, enzyme is cut the back purified product and is connected with the product of annealing.Ligation is following: get 1-20 μ l annealing product, 1-20 μ l carrier enzyme and cut back purified product, 1-20 μ l ligase enzyme, 1-20 μ l and connect damping fluid, add at last deionized water to 10-200 μ l in 16 ℃ of connections of spending the night.Connect product and transform DH5 α intestinal bacteria, utilize amicillin resistance label screening positive colony, enzyme was cut evaluation after a small amount of was extracted plasmid, like Fig. 3 and Fig. 4.With identifying that correct clone's carries out large quantity extracting plasmid.
Research shows: the unusual synthetic major cause that is malignant tumour propagation, soaks into, shifts of tumour CA, and be one of important symbol of its vicious transformation.Special tumour CA synthetic is by the specificity decision of glycosyltransferase, and the synthetic level of CA is relevant with the expression regulation of glycosyltransferase gene.FUT1/FUT4 is the key enzyme of synthetic LeY tumour oligosaccharides.FUT1 is α 1, and the fucosylated glycosyltransferase of 2-(α 1,2-FUT), and synthetic relevant with terminal α 1,2 fucosido of LeY tumour oligosaccharides antigen, catalyzed synthesizing alpha 1,2-Fucose glycosidic bond; And FUT4 is α 1, and the fucosylated glycosyltransferase of 3-(α 1,3-FUT), and catalyzed synthesizing alpha 1,3-Fucose glycosidic bond.LeY tumour oligosaccharides antigen is the sugar chain composition in the cell surface saccharide complex (gp, glycolipid and proteoglycan); Have been found that its resulting anomaly in kinds of tumors increases, closely related with tumor proliferation, infiltration, transfer, clinical stages (classification) and prognosis.Therefore, will be effective target spot to reduce the antigenic resultant quantity of LeY tumour oligosaccharides through downward modulation FUT1 and FUT4 expression level, the research of this aspect does not appear in the newspapers at present both at home and abroad as yet.The present invention utilizes the RNA interference technique, makes up reorganization FUT1 and FUT4 interfere plasmid, and through suppressing the synthetic and expression of the special fucosyltransferase of tumour cell, it is antigenic synthetic to reduce LeY tumour oligosaccharides, and then suppresses growth of tumor, infiltration and transfer.
The present invention compares prior art and has following advantage: adopt the present invention to make up the FUT1 of reorganization and target gene therapy that the FUT interfere plasmid is clinical tumor provides new thinking and means; Not only effect is obvious but also toxic side effect is little for it, safety; Patient treatment cycle weak point is a kind of efficient, safe, economic antitumor pattern simultaneously.
Description of drawings
Fig. 1 is the site plan of dna profiling sequence on gene of the interfere plasmid of FUT1 gene of the present invention.
Fig. 2 is the site plan of dna profiling sequence on gene of the interfere plasmid of FUT4 gene of the present invention.
Fig. 3 is that the interfere plasmid enzyme of FUT1 gene of the present invention is cut identification and analysis figure.
Fig. 4 is that the interfere plasmid enzyme of FUT4 gene of the present invention is cut identification and analysis figure.
Fig. 5 is a FUT1 Gene RT-PCR analysis behind the interfere plasmid transfection A431 tumour cell of the present invention.
Fig. 6 is a FUT4 Gene RT-PCR analysis behind the interfere plasmid transfection A431 tumour cell of the present invention.
Fig. 7 is that LeY resultant quantity fluidic cell detects figure behind FUT1 interfere plasmid of the present invention (FUT1-1 and FUT1-2) the transfection A431 tumour cell.
Fig. 8 is that LeY resultant quantity fluidic cell detects figure behind FUT4 interfere plasmid of the present invention (FUT4-1 and FUT4-2) the transfection A431 tumour cell.
Fig. 9 is the inhibiting figure of FUT1 interfere plasmid of the present invention (FUT1-1 and FUT1-2) transfection A431 growth of tumour cell.
Figure 10 is the inhibiting figure of FUT4 interfere plasmid of the present invention (FUT4-1 and FUT4-2) transfection A431 growth of tumour cell.
Figure 11 is the figures of the different interfere plasmids of FUT1 of the present invention to the effect of PCNA (PCNA) expression inhibiting.
Figure 12 is the inhibiting figure that the different interfere plasmids of FUT4 of the present invention are expressed PCNA (PCNA).
Figure 13 is that the present invention influences the analysis that the mouse tumor volume is respectively organized in experimentation on animals.
Figure 14 is that the present invention influences the analysis that mouse tumor weight is respectively organized in experimentation on animals.
Embodiment
Example 1 makes up reorganization FUT1 interfere plasmid
1. obtain to be used for the dna profiling sequence of the reorganization FUT1 interfere plasmid of neoplasm growth according to the SiRNA design software, it is the structure that carries out interfere plasmid with the sequence of the control region of above-mentioned FUT1 gene and coding region.The 5` end of every chain contains the restriction enzyme site (underscore marks) of HindIII or BamHI.Specific as follows:
FUT1-1(5’-3’)
GATCCTGGCCGGTTTGGTAATCAGTTCAAGAGACTGATTACCAAACCGGCCAGGA
AGCTTCCTGGCCGGTTTGGTAATCAGTCTCTTGAACTGATTACCAAACCGGCCAG
FUT1-2(5’-3’)
GATCCAGACTTTGCCCTGCTCACATTCAAGAGATGTGAGCAGGGCAAAGTCTGGA
AGCTTCCAGACTTTGCCCTGCTCACATCTCTTGAATGTGAGCAGGGCAAAGTCTG
2. insert the dna profiling sequence of the FUT1 interfere plasmid of carrier according to the design of pSilencer-4.1-CMV-neo carrier structure information; Promptly the polyclone restriction enzyme site (HindIII, BamH I) with interference vector is the basis; Design the dna sequence dna that the FUT1SiRNA template of identical sticky end is arranged with interference vector, make up the interfere plasmid of pSilencer-4.1-FUT1-1 and pSilencer-4.1-FUT1-2 respectively.
3. after the special sequence synthetic (Takara company), form the double chain DNA sequence of the SiRNA template of 55bp (containing sticky end HindIII, BamH I) through sex change, annealing.Synthetic is used to disturb two chains of template DNA sequence of the SiRNA of FUT1 gene, uses 100 μ l deionized water dissolvings respectively, get 1 μ l deionized water by 1: 10 volume ratio dilution; Measure the light absorption value of 260nm, calculate its DNA concentration (about 33 μ g/ml), be diluted to 80ng/ μ l with deionized water; Drawing every chain 10 μ l adds 100 μ l, 1 * DNA annealing buffer and (contains 10mM Tris (pH7.4); 50mM NaCl, 1mM EDTA), is cooled to 37 ℃ and kept 1 hour in 98 ℃ of sex change 3 minutes; Preserve this annealing product in-20 ℃ of temperature, subsequent use.
4. pSilencer-4.1-FUT1 reorganization interfere plasmid makes up
PSilencer-4.1-CMV-neo (90ng) was carried out HindIII and BamHI double digestion 2 hours in 37 ℃; Enzyme is cut back recovery product and is connected with the annealing product; Ligation is following: get 2 μ l annealing product, 2 μ l carrier enzymes and cut back purifying and recovering product, 2 μ l ligase enzymes, 2 μ l and connect damping fluid, add 2 μ l deionized water to 10 μ l at last in 16 ℃ of connections of spending the night.Connect product and transform DH5 α intestinal bacteria, utilize penbritin (Amp) resistance screening positive colony, enzyme was cut evaluation after a small amount of was extracted plasmid.With identifying the correct sub-large quantity extracting plasmid of clone.
Example 2 makes up reorganization FUT4 interfere plasmid
1. obtain to be used for the dna profiling sequence of the reorganization FUT4 interfere plasmid of neoplasm growth according to the SiRNA design software, it is the structure that carries out interfere plasmid with the sequence of the control region of above-mentioned FUT4 gene and coding region.The 5` end of every chain contains the restriction enzyme site (underscore marks) of HindIII or BamH I.Specific as follows:
FUT4-1(5’-3’)
GATCCGCCTGGCAAGTAACCTCTTCTCAAGAGAAAGAGGTTACTTGCCAGGCGGA
AGCTTCCAGCCTGGCAAGTAACCTCTTTCTCTTGAGAAGAGGTTACTTGCCAGGCG
FUT4-2(5`-3`)
GATCCGTAACCTCTTCAACTGGACTTCAAGAGAGTCCAGTTGAAGAGGTTACGGA
AGCTTCCGTAACCTCTTCAACTGGACTCTCTTGAAGTCCAGTTGAAGAGGTTACG
2. insert the dna profiling sequence of the FUT4 interfere plasmid of carrier according to the design of pSilencer-4.1-CMV-neo carrier structure information; Promptly the polyclone restriction enzyme site (HindIII, BamHI) with interference vector is the basis; Design the dna sequence dna that the FUT4SiRNA template of identical sticky end is arranged with interference vector, make up the interfere plasmid of pSilencer-4.1-FUT4-1 and pSilencer-4.1-FUT4-2 respectively.
3. after the special sequence synthetic (Takara company), form the double chain DNA sequence of the SiRNA template of 55bp (containing sticky end HindIII, BamH I) through sex change, annealing.Synthetic is used to disturb two chains of template DNA sequence of the SiRNA of FUT4 gene, uses 50 μ l deionized water dissolvings respectively, get 0.5 μ l deionized water by 1: 10 volume ratio dilution; Measure the light absorption value of 260nm, calculate its DNA concentration, be diluted to 100ng/ μ l with deionized water; Drawing every chain 10 μ l adds 46 μ l, 1 * DNA annealing buffer and (contains 10mM Tris (pH7.4); 50mM NaCl, 1mM EDTA), is cooled to 37 ℃ and kept 1 hour in 90 ℃ of sex change 10 minutes; Preserve this annealing product in-20 ℃ of temperature, subsequent use.
4. pSilencer-4.1-FUT4SiRNA reorganization interfere plasmid makes up
PSilencer-4.1-CMV-neo (300ng) was carried out HindIII and BamHI double digestion 3 hours in 37 ℃; Enzyme is cut back recovery product and is connected with the annealing product; Ligation is following: get 5 μ l annealing product, 5 μ l carrier enzymes and cut the back and reclaim product, 5 μ l ligase enzymes, 5 μ l and connect damping fluid, add de-ionized to 50 μ l at last in 16 ℃ of connections of spending the night.Connect product and transform DH5 α intestinal bacteria, utilize penbritin (Amp) resistance marker screening positive clone, enzyme was cut evaluation after a small amount of was extracted plasmid.With identifying the correct sub-large quantity extracting plasmid of clone.
Below be detected result of the present invention:
1.pSilencer-4.1-FUT1/FUT4SiRNA recombinant plasmid transfection A431 tumour cell, the cell FUT1/FUT4 that adopts RT-PCR to detect discovery transfection recombinant plasmid expresses obviously and descends, like Fig. 5 and shown in Figure 6.
2.pSilencer-4.1-FUT1/FUT4SiRNA behind the recombinant plasmid transfection A431 tumour cell, adopt Flow Cytometry to detect and find that the synthetic of LeY significantly reduces, like Fig. 7 and shown in Figure 8.
3.pSilencer-4.1-FUT1/FUT4SiRNA recombinant plasmid transfection A431 tumour cell detects the cell growth that shows the transfection recombinant plasmid through tetrazolium bromide (MTT) colourimetry and significantly reduces, like Fig. 9 and shown in Figure 10.
4.pSilencer-4.1-FUT1/FUT4SiRNA recombinant plasmid transfection A431 tumour cell adopts the expression amount of Western blot scientific discovery PCNA obviously to reduce, like Figure 11 and shown in Figure 12.
5.pSilencer-4.1-FUT1-1/FUT4-1 recombinant plasmid suppresses tumor growth effect in the animal model
(1) with trysinization A431 tumour cell, centrifugal collecting cell prepares cell suspension with saline water, and counts with trypan blue method pair cell, makes that to contain the A431 number of cells in every 0.1ml saline water be 2 * 10 6Get the 4-6 nude mice (n=6~8) in age in week, every the right armpit skin of mouse injected 0.1ml tumour cell suspension.Control group equivalent injecting normal saline.
(2) experiment is divided into four groups: blank control group, empty carrier group, FUT1-1 interfere plasmid group and FUT4-1 interfere plasmid group.Injection A431 tumour cell suspension next day, whenever injected interfere plasmid (g/ time/mouse of 150 μ), totally 10 times at a distance from 1 day.(3) every day observation experiment group and control group mouse growth conditions, plantation tumour size variation, and weigh.Therapy lasted was put to death nude mice after 22 days, and measured knurl volume (table 1) and measure tumor weight (table 2).
The analysis of knurl volume is respectively organized in table 1 experiment
Figure RE-GSA00000013403000111
Annotate: * * representes P<0.01, and difference is extremely remarkable.
Figure 13 is seen in the comparative analysis of the knurl volume of experimental group and control group.
The analysis of tumor weight is respectively organized in table 2 experiment
Figure RE-GSA00000013403000121
Annotate: * * representes (P<0.01), and difference is extremely remarkable.
Figure 14 is seen in the comparative analysis of the tumor weight of experimental group and control group.
Tumour inhibiting rate=(the average knurl of the average knurl weight-experimental group of control group is heavy)/average knurl of control group heavy * 100%
Obtaining FUT1-1 plasmid group tumour inhibiting rate thus is 52.8%, with the poor heteropole of control group remarkable (P<0.01); FUT4-1 plasmid group tumour inhibiting rate is 45.0%, with the poor heteropole of control group remarkable (P<0.01).
SEQUENCE?LISTING
< 110>swallow, the autumn
< 120>be used to suppress the RNA interference sequence of LeY CA synthetic fucosyl transferase I and recombinate and interfere
<130>201010108936.8
<140>201010108936.8
<141>2010-01-27
<160>28
<170>PatentIn?version?3.3
<210>1
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>1
tggccggttt?ggtaatcag 19
<210>2
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>2
agactttgcc?ctgctcaca 19
<210>3
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>3
gaggagtacg?cggacttga 19
<210>4
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>4
cagatccgca?gagagttca 19
<210>5
<21>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>5
cggcatggag?tggtgtaaa 19
<210>6
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>6
tggccttcct?gctagtctg 19
<210>7
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>7
ttcgcctttc?ctcccctgc 19
<210>8
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>8
gcctggcaag?taacctctt 19
<210>9
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>9
gtaacctctt?caactggac 19
<210>10
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>10
cggacgtctt?tgtgcctta 19
<210>11
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>11
catgtgaccg?tggacgtgt 19
<210>12
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>12
gttctacctg?gctttcgag 19
<210>13
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>13
ctcgtacctg?cttttcctc 19
<210>14
<211>19
<212>DNA
<213>human
<220>
<221>iDNA
<222>(1)..(19)
<400>14
gcggaggcag?cgctgcctg 19
<210>15
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>15
gatcctggcc?ggtttggtaa?tcagttcaag?agactgatta?ccaaaccggc?caggaagctt 60
cctggccggt?ttggtaatca?gtctcttgaa?ctgattacca?aaccggccag 110
<210>16
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>16
gatccagact?ttgccctgct?cacattcaag?agatgtgagc?agggcaaagt?ctggaagctt 60
ccagactttg?ccctgctcac?atctcttgaa?tgtgagcagg?gcaaagtctg 110
<210>17
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>17
gatccgagga?gtacgcggac?ttgattcaag?agatcaagtc?cgcgtactcc?tcggaagctt 60
ccgaggagta?cgcggacttg?atctcttgaa?tcaagtccgc?gtactcctcg 110
<210>18
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>18
gatcccagat?ccgcagagag?ttcattcaag?agatgaactc?tctgcggatc?tgggaagctt 60
cccagatccg?cagagagttc?atctcttgaa?tgaactctct?gcggatctgg 110
<210>19
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>19
gatcccggca?tggagtggtg?taaattcaag?agatttacac?cactccatgc?cgggaagctt 60
cccggcatgg?agtggtgtaa?atctcttgaa?tttacaccac?tccatgccgg 110
<210>20
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>20
gatcctggcc?ttcctgctag?tctgttcaag?agacagacta?gcaggaaggc?caggaagctt 60
cctggccttc?ctgctagtct?gtctcttgaa?cagactagca?ggaaggccag 110
<210>21
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>21
gatccttcgc?ctttcctccc?ctgcttcaag?agagcagggg?aggaaaggcg?aaggaagctt 60
ccttcgcctt?tcctcccctg?ctctcttgaa?gcaggggagg?aaaggcgaag 110
<210>22
<211>111
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>22
gatccgcctg?gcaagtaacc?tcttctcaag?agaaagaggt?tacttgccag?gcggaagctt 60
ccagcctggc?aagtaacctc?tttctcttga?gaagaggtta?cttgccaggc?g 111
<210>23
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>23
gatccgtaac?ctcttcaact?ggacttcaag?agagtccagt?tgaagaggtt?acggaagctt 60
ccgtaacctc?ttcaactgga?ctctcttgaa?gtccagttga?agaggttacg 110
<210>24
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>24
gatcccggac?gtctttgtgc?cttattcaag?agataaggca?caaagacgtc?cgggaagctt 60
cccggacgtc?tttgtgcctt?atctcttgaa?taaggcacaa?agacgtccgg 110
<210>25
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>25
gatcccatgt?gaccgtggac?gtgtttcaag?agaacacgtc?cacggtcaca?tgggaagctt 60
cccatgtgac?cgtggacgtg?ttctcttgaa?acacgtccac?ggtcacatgg 110
<210>26
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>26
gatccgttct?acctggcttt?cgagttcaag?agactcgaaa?gccaggtaga?acggaagctt 60
ccgttctacc?tggctttcga?gtctcttgaa?ctcgaaagcc?aggtagaacg 110
<210>27
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>27
gatccctcgt?acctgctttt?cctcttcaag?agagaggaaa?agcaggtacg?agggaagctt 60
ccctcgtacc?tgcttttcct?ctctcttgaa?gaggaaaagc?aggtacgagg 110
<210>28
<211>110
<212>DNA
<213>human
<220>
<221>iDNA
<222>(6)..(23)
<220>
<221>iDNA
<222>(63)..(81)
<400>28
gatccgcgga?ggcagcgctg?cctgttcaag?agacaggcag?cgctgcctcc?gcggaagctt 60
ccgcggaggc?agcgctgcct?gtctcttgaa?caggcagcgc?tgcctccgcg 110

Claims (4)

1. a fucosyl transferase I that is used to suppress the constructed reorganization of LeY tumour oligosaccharides antigen synthetic fucosyl transferase I is interfered sequence FUT1-1, and it is characterized in that: its sequence is following: TGGCCGGTTTGGTAATCAG.
2. a kind of fucosyl transferase I interfere plasmid that is used to suppress the constructed reorganization of LeY tumour oligosaccharides antigen synthetic fucosyl transferase I of claim 1; It is characterized in that: it is that the special restriction enzyme site of polyclone with RNA interference vector pSilencer-4.1-CMV-neo is the basis; Design the dna sequence dna that the FUT1 SiRNA template of identical sticky end is arranged with interference vector, make up the interfere plasmid that contains FUT1-1 interference sequence of 1 FUT1: pSilencer-4.1-FUT1-1.
3. claim 1 a kind of is used to suppress the preparation method of the fucosyl transferase I interfere plasmid of the constructed reorganization of LeY tumour oligosaccharides antigen synthetic fucosyl transferase I; It is characterized in that: 1. be used to interfere the FUT1-1 of FUT1 gene to interfere the template DNA of sequence synthetic,, measure the light absorption value of 260nm with deionized water or the dissolving of TE damping fluid; And calculating DNA concentration; 2. the sample of getting after the dissolving adds in the DNA annealing buffer, and in 90-98 ℃ of sex change 3-10 minute, cooling back cryopreservation was subsequent use; 3. RNA interference vector pSilencer-4.1-CMV-neo is carried out special digestion with restriction enzyme in 37 ℃; Produce and the sticky end of interfering sequences match, 4. enzyme cut behind the product purification with 2. in the product preserved of preparation be connected, 5. with above-mentioned connection product transformed competence colibacillus bacterium and utilize the resistance marker screening positive clone of carrier; 6. extract and carry out enzyme behind the plasmid and cut evaluation, 7. cut and identify correct clone's preparation plasmid with enzyme.
4. a kind of fucosyl transferase I interfere plasmid that is used for suppressing the constructed reorganization of LeY tumour oligosaccharides antigen synthetic fucosyl transferase I of claim 2 is in the application for preparing antitumor drug.
CN2010101089368A 2007-01-15 2007-01-15 RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens Expired - Fee Related CN102094020B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010101089368A CN102094020B (en) 2007-01-15 2007-01-15 RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101089368A CN102094020B (en) 2007-01-15 2007-01-15 RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007100100993A Division CN101225383B (en) 2007-01-15 2007-01-15 RNA interference sequence and recombinant interference plasmid of fucosyl transferase I and IV for suppressing synthesis of LeY carbohydrate antigen

Publications (2)

Publication Number Publication Date
CN102094020A CN102094020A (en) 2011-06-15
CN102094020B true CN102094020B (en) 2012-11-28

Family

ID=44127287

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010101089368A Expired - Fee Related CN102094020B (en) 2007-01-15 2007-01-15 RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens

Country Status (1)

Country Link
CN (1) CN102094020B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111840210B (en) * 2020-05-31 2022-07-15 王磊 Novel immune medicine for treating solid tumor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0654082A1 (en) * 1992-07-20 1995-05-24 The Regents Of The University Of Michigan CLONING AND EXPRESSION OF A HUMAN $g(a)(1,3)FUCOSYLTRANSFERASE, FUCT-VI
CN1360633A (en) * 1999-02-18 2002-07-24 弗里德里希·阿尔特曼 Fucosyl transferase gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0654082A1 (en) * 1992-07-20 1995-05-24 The Regents Of The University Of Michigan CLONING AND EXPRESSION OF A HUMAN $g(a)(1,3)FUCOSYLTRANSFERASE, FUCT-VI
CN1360633A (en) * 1999-02-18 2002-07-24 弗里德里希·阿尔特曼 Fucosyl transferase gene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刁斌等.Ley抗原与肿瘤诊治过程中作用的研究进展.《中国现代医生》.2008,第46卷(第16期),59-60. *

Also Published As

Publication number Publication date
CN102094020A (en) 2011-06-15

Similar Documents

Publication Publication Date Title
CN103937872A (en) Application of Crm1 to stomach cancer diagnosis and treatment
CN104975023B (en) Human cervical carcinoma shifts relevant new long-chain non-coding RNA sequence, separation method and application thereof
CN101633923A (en) Long non-coding RNA sequence relevant to human melanoma cells and application thereof
CN113416768B (en) Application of PRKRA gene as target in inhibiting replication of peste des petits ruminants virus
CN105861551B (en) The carrier and its construction method of Combined expression microRNAs inhibition Cells Proliferation of Human Breast Cancer and application
CN102094020B (en) RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase I synthesized by LeY carbohydrate antigens
CN101225383B (en) RNA interference sequence and recombinant interference plasmid of fucosyl transferase I and IV for suppressing synthesis of LeY carbohydrate antigen
CN102094019B (en) RNA (Ribose Nucleic Acid) interference sequence and recombined interference plasmid for inhibiting fucosyltransferase IV synthesized by LeY carbohydrate antigens
CN108220446A (en) Applications of the LINC01356 as molecular marker in gastric cancer
CN104056277A (en) MLH1 gene or application of expression product in colorectal cancer highly expressed by DKK4
CN106167822A (en) A kind of long-chain non-coding RNA and application thereof
CN104911183B (en) Suppress the shRNA of cancer of pancreas TAK1 gene expressions transcription templates
CN103405784B (en) Use of c-Fos gene in preparation of anti-cancer drugs
US20160348085A1 (en) Recombinant l-asparaginase from zymomonas
CN101892226A (en) Small interfering RNA (siRNA) for restraining ACC gene expression of human adipocyte and expression vector and application thereof
CN105506088B (en) Chicken B subgroup avian leucosis resistance molecules mark tvb3667-3668insAGAnd its molecular diagnosis method
CN100496614C (en) Small interference RNA molecule for restraining protein expression of DNA-PKCS, and encoding gene and application
CN102796748A (en) Wheat non-specific lipid transfer protein gene and coded protein and application thereof
CN105002181B (en) A kind of rat Kif11 genes interference shRNA and its recombinant adeno-associated virus and antitumor application thereof
CN100395335C (en) siRNA double-chain for suppressing bc1-2 gene expression
CN100410373C (en) siRNA double-chain for suppressing bc1-2 gene expression
CN102286435A (en) Regulatory-cytokine-induced anti-apoptotic molecule (CIAPIN1) recombinant adenovirus and preparation method and use thereof
CN108588221A (en) use of STI L gene and related medicine
JP2018530343A (en) Pharmaceutical composition for cancer treatment comprising RNA oligonucleotide
CN100395334C (en) siRNA double-chain for suppressing bc1-2 gene expression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121128

Termination date: 20160115

EXPY Termination of patent right or utility model